New Research Points to a Potential Way to Protect Insulin-Producing Cells from Damage
Scientists found that blocking a protein called heparanase may help shield pancreatic beta cells from the inflammation and oxidative stress that drive Type 1 diabetes. Early results in human tissue samples show promise.
Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.
Key takeaways
- Heparanase is an enzyme involved in breaking down protective structures around insulin-producing cells and amplifying inflammation in the pancreas.
- Two experimental compounds (L15 and L17) that block heparanase reduced oxidative stress and preserved insulin secretion in human pancreatic tissue samples.
- These compounds worked by calming immune cells and reducing harmful reactive oxygen species (ROS) that damage beta cells.
- This research is early-stage laboratory work and does not yet represent a treatment available to patients.
What Damages Beta Cells in Type 1 Diabetes?
In Type 1 diabetes, the immune system mistakenly attacks the insulin-producing beta cells in the pancreas. This inflammatory attack involves multiple harmful processes happening at once: immune cells release damaging molecules, oxidative stress builds up inside cells, and structural support systems break down. Understanding each of these mechanisms is crucial to finding ways to protect beta cells.
One enzyme that researchers have been studying is called heparanase (HPSE). This enzyme degrades heparan sulfate, a protective molecule that surrounds and stabilizes cells in the pancreas. When heparanase activity increases during inflammation, it appears to accelerate beta cell damage and intensify the inflammatory environment—creating a vicious cycle that worsens the attack on insulin-producing cells.
How Do These New Compounds Work?
In this study, researchers tested two experimental compounds called L15 and L17, which are designed to block heparanase activity. The researchers tested these compounds in lab models of beta cell injury and in human pancreatic tissue samples taken from organ donors.
The compounds worked on multiple fronts. First, they reduced the activation of pro-inflammatory immune cells called M1 macrophages, which are key drivers of inflammation in the pancreas. By calming these immune cells, the compounds reduced the production of damaging inflammatory signals. Second, the compounds lowered the levels of reactive oxygen species (ROS)—harmful molecules that accumulate inside beta cells and damage their internal structures. Third, the compounds helped preserve the structural organization inside beta cells and prevented them from undergoing apoptosis, a form of programmed cell death.
What Did the Research Show in Human Tissue?
The most important part of this study involved testing the compounds in human pancreatic islets—tissue samples containing real insulin-producing beta cells. Under inflammatory conditions designed to mimic the Type 1 diabetes environment, both L15 and L17 preserved the protective heparan sulfate around cells, reduced oxidative stress, and maintained the ability of islets to respond to glucose by secreting insulin. L17 showed greater protective effects than L15.
These results are encouraging because they show that blocking heparanase can simultaneously address multiple aspects of beta cell damage: reducing inflammation, lowering oxidative stress, and preserving the cells' core function of producing insulin.
What Does This Mean for Type 1 Diabetes Treatment?
This is early-stage research. The compounds have been tested in laboratory models and in human tissue samples in a dish, but they have not been tested in living people. Much more work is needed to understand whether blocking heparanase can slow or prevent Type 1 diabetes onset in real patients, what dose would be safe and effective, and whether such an approach could be combined with other therapies.
The research does suggest a new target—heparanase—that might be worth pursuing as scientists continue searching for ways to protect beta cells. The fact that the compounds worked on multiple levels of damage simultaneously suggests they could potentially be part of a broader protective strategy, though any future treatment would need to be rigorously tested for safety and effectiveness in clinical trials.
Evidence label
Source: ACS pharmacology & translational science. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.
Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.
From Type1Cure
Related reading
More evidence-labeled coverage across the Type1Cure library.
- Research summaryCauses & What We KnowPregnant Women with Diabetes Show Higher Rates of Toxoplasma InfectionPubMed indexed literature
- Research summaryCauses & What We KnowExploring Rare Breast Inflammation: What BRCA Mutations and Type 1 Diabetes May SharePubMed indexed literature
- Research summaryCauses & What We KnowUnderstanding Type 1 Diabetes: A Shift Toward Early InterventionPubMed indexed literature
- Research summaryCauses & What We KnowHow Nutrition, Metabolism, and Immunity Connect: What the Lectin Pathway Tells UsPubMed indexed literature
- Research summaryCauses & What We KnowHow Gut Bacteria May Influence the Intestinal Barrier in Type 1 DiabetesPubMed indexed literature
- Research summaryCauses & What We KnowLiver Changes in Cystic Fibrosis: What a New Study FoundPubMed indexed literature